New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination

Kaminetsky, Joshua; Rudikoff, Donald

doi:10.1002/ccr3.4865

Cited by 34 publications

(39 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three of five erythema multiforme cases were associated with the mRNA-1273 vaccine [ 1 , 62 , 63 ]. New onset of prurigo nodularis [ 17 ], radiation recall dermatitis [ 64 ], symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)-like eruption [ 65 ], Stevens-Johnson syndrome/toxic epidermal necrolysis [ 66 , 67 , 68 ], Sweet’s syndrome [ 69 , 70 ], vitiligo [ 71 ], vasculitis [ 50 , 72 , 73 ], livedo racemosa [ 27 ], fixed drug eruption [ 27 ], pityriasis rubra pilaris-like eruption [ 74 ], and facial pustular neutrophilic eruption [ 75 ] have been reported post-vaccination. All SJS and Sweet’s syndrome cases were managed successfully.…”

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca–Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Of interest, there have been multiple cases reporting new-onset of vitiligo within several days to 1 week after patients received first doses of COVID-19 messenger RNA vaccinations. 9,10 We postulate that this patient's atypical history and sequential relationship of SARS-CoV-2 infection to onset of vitiligo, in conjunction with the existence of robust pathophysiologic theories to explain the phenomenon, support the diagnosis of COVID-induced vitiligo.…”

Section: Discussionmentioning

confidence: 83%

Vitiligo following COVID-19: A case report and review of pathophysiology

et al. 2022

View full text Add to dashboard Cite

“…Immune mechanisms such as antigen presentation, cytokine production, epitope spreading, and polyclonal activation of B cells are involved in both the anti-infectious immune response as well as in autoreactivity [4]. In the case of vitiligo, Kaminetsky and Rudikoff have postulated that specifically, melanocytes may become unintentional targets for antibodies and immune cells newly produced by the vaccine [2]. Given that the development of vitiligo involves the destruction of melanocytes by autoreactive CD8+ T cells and successful vaccination also involves an extensive CD8+ T-cell response, this hypothesis may be plausible [5].…”

Section: Case Presentationmentioning

confidence: 99%

Vitiligo Possibly Triggered by COVID-19 Vaccination

Militello¹,

Ambur²,

Steffes³

2022

Cureus

View full text Add to dashboard Cite

Several cutaneous manifestations following COVID-19 vaccination have been cited in the literature since the beginning of the pandemic. Two case reports regarding the development of vitiligo after receiving the COVID-19 vaccine. Herein, we present a case report of a patient who developed new-onset vitiligo two weeks after receiving her COVID-19 vaccine. Although the pathogenesis is unclear, it may be related to the inflammatory cells involved in both the pathogenesis of vitiligo and the mechanism by which the COVID-19 vaccine stimulates the immune system. This case report highlights the need for further investigation into the link between COVID-19 and the development of vitiligo.

show abstract

New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination

Cited by 34 publications

References 4 publications

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Vitiligo following COVID-19: A case report and review of pathophysiology

Vitiligo Possibly Triggered by COVID-19 Vaccination

Contact Info

Product

Resources

About